Richard Heyman
Founder at ORIC PHARMACEUTICALS, INC.
Net worth: 7 M $ as of 2023-05-30
Profile
Richard A.
Heyman is the founder of Syndax Pharmaceuticals, Inc. (founded in 2005), X-Ceptor Therapeutics, Inc. (founded in 1999), Aragon Pharmaceuticals, Inc. (founded in 2009), Seragon Pharmaceuticals, Inc. (founded in 2013), Metacrine, Inc. (founded in 2014), and Oric Pharmaceuticals, Inc. (founded in 2014).
He held various titles at these companies, including Director, Chief Scientific Officer & Senior VP-Research, President, CEO, Head-Research & Development, and President, Chief Executive Officer & Director.
Dr. Heyman's current job(s) include Vice Chairman-Trustees Board at The Salk Institute for Biological Studies (since 2015), Chairman at PMV Pharmaceuticals, Inc. (since 2020), Chairman at Enliven Therapeutics, Inc. (since 2023), Director at BIOCOM, Amunix, Inc., Jewish Federation of Omaha, Inc., American Association For Cancer Research Foundation, Yumanity, Inc., and Vividion Therapeutics, Inc. He is also a Venture Partner at ARCH Venture Partners LLC and an Advisor at aTyr Pharma, Inc. He is a Member-Board of Visitors at Moores Cancer Center.
Dr. Heyman's former job(s) include Chairman at Amunix Pharmaceuticals, Inc., Chairman at Rayzebio, Inc. (from 2022 to 2024), Independent Director at Receptos LLC (from 2014 to 2015), Independent Director at Organovo Holdings, Inc. (from 2013 to 2016), Independent Director at Gritstone bio, Inc. (from 2015 to 2022), Director at Yumanity Holdings LLC, Director at Mavupharma, Inc. (in 2017), Director at Millendo Therapeutics, Inc., Independent Director at BCTG Acquisition Corp., and Independent Director at Yumanity Therapeutics, Inc. (from 2016 to 2022).
He also served as Vice President-Research at Ligand Pharmaceuticals, Inc. and Senior Vice President-Drug Discovery at Kalypsys, Inc. (from 1999 to 2006).
Dr. Heyman's education includes an undergraduate degree from the University of Connecticut and a doctorate degree from the University of Minnesota.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-14 | 203,129 ( 0.49% ) | 4 M $ | 2024-03-30 | |
ORIC PHARMACEUTICALS INC
0.34% | 2024-03-30 | 228,772 ( 0.34% ) | 3 M $ | 2024-03-30 |
METACRINE INC
0.39% | 2023-02-02 | 165,683 ( 0.39% ) | 92 285 $ | 2023-05-30 |
2024-04-09 | 10,050 ( 0.02% ) | 17 085 $ | 2024-03-30 |
Richard Heyman active positions
Companies | Position | Start |
---|---|---|
ORIC PHARMACEUTICALS, INC. | Founder | 2013-12-31 |
PMV PHARMACEUTICALS, INC. | Chairman | 2020-05-31 |
ENLIVEN THERAPEUTICS, INC. | Chairman | 2023-02-22 |
ATYR PHARMA, INC. | Consultant / Advisor | - |
Jewish Federation of Omaha, Inc.
Jewish Federation of Omaha, Inc. Miscellaneous Commercial ServicesCommercial Services Jewish Federation of Omaha, Inc. offers social, educational and cultural programs through fundraising. It supports communal services in the Omaha area by establishing and accumulating assets for permanent funding resources. The company was founded in 1903 and is headquartered in Omaha, NE. | Director/Board Member | - |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Director/Board Member | 2022-01-18 |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin. | Private Equity Analyst | - |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | Director/Board Member | - |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Director/Board Member | - |
░░░░░░░░ ░░░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Richard Heyman
Companies | Position | End |
---|---|---|
░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Richard Heyman
University of Connecticut | Undergraduate Degree |
University of Minnesota | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 10 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
ATYR PHARMA, INC. | Health Technology |
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
ORGANOVO HOLDINGS, INC. | Health Technology |
PMV PHARMACEUTICALS, INC. | Commercial Services |
GRITSTONE BIO, INC. | Health Technology |
ORIC PHARMACEUTICALS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
ENLIVEN THERAPEUTICS, INC. | Health Technology |
METACRINE, INC. | Health Technology |
Private companies | 20 |
---|---|
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin. | Finance |
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | Health Technology |
Jewish Federation of Omaha, Inc.
Jewish Federation of Omaha, Inc. Miscellaneous Commercial ServicesCommercial Services Jewish Federation of Omaha, Inc. offers social, educational and cultural programs through fundraising. It supports communal services in the Omaha area by establishing and accumulating assets for permanent funding resources. The company was founded in 1903 and is headquartered in Omaha, NE. | Commercial Services |
Seragon Pharmaceuticals, Inc.
Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
Yumanity Holdings LLC
Yumanity Holdings LLC Medical/Nursing ServicesHealth Services Yumanity Holdings LLC provides healthcare services. The company was founded in 2015 and is headquartered in Cambridge, MA. | Health Services |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
BCTG Acquisition Corp.
BCTG Acquisition Corp. Financial ConglomeratesFinance BCTG Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in May 2020 and is headquartered in San Diego, CA. | Finance |
Yumanity Therapeutics, Inc.
Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
Moores Cancer Center | |
American Association For Cancer Research Foundation |
- Stock Market
- Insiders
- Richard Heyman